Clinical Trials Logo
  1. Home
  2. Meningococcal Infection
  3. NCT02531698

A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years

MENINGOCOCCAL INFECTION Clinical Trial

Official title:
A Phase 2, Randomized, Controlled, Observer-blinded Study To Describe The Immunogenicity, Safety, And Tolerability Of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent Rlp2086) In Healthy Subjects Aged >/= 24 Months To <10 Years

Clinical Trial Summary

This study is looking at a new vaccine that might prevent meningococcal disease, and will study the immune response elicited by this vaccine when given to healthy young children. The study will also look at the safety of the new vaccine as well as how it is tolerated.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02531698
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 2
Start date August 2015
Completion date March 2017
View Details
See also
  Status Clinical Trial Phase
Completed NCT01543087 - Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose Phase 3
Completed NCT01442675 - Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine Phase 2
Completed NCT00359983 - Long-Term Antibody Persistence at 1, 3 and 5 Years After a Fourth Dose of GSK Biologicals' Hib-MenCY-TT Vaccine Compared to ActHIB Phase 3
Recruiting NCT06128733 - Study of an Investigational Pentavalent Meningococcal ABCYW Vaccine in Adults and Adolescents Phase 1/Phase 2
Completed NCT00715234 - Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients N/A
Completed NCT01359449 - Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizations Phase 3
Recruiting NCT04843111 - Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)
Completed NCT01890759 - Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation Phase 3
Completed NCT01086969 - A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India Phase 3
Completed NCT00700635 - Dose Comparison Study of Menactra® in US Children Phase 2
Completed NCT00310635 - Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Age Phase 4
Completed NCT01659996 - Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age Phase 4
Completed NCT00345683 - Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age. Phase 3
Completed NCT01340898 - Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With Routine Vaccines in Healthy Infants and Toddlers Phase 3
Completed NCT00392808 - Immunogenicity of the Booster Dose of Two MenC Vaccines Phase 4
Completed NCT00258856 - Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Menomune® Phase 2
Completed NCT06228586 - Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in Vietnam Phase 3
Completed NCT00806195 - Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants Phase 3
Completed NCT00269477 - Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menomune® Phase 2
Completed NCT00643916 - Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age Phase 2